DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
Relevance. Drug-induced liver injury (DILI) is a potentially serious clinical condition that remains a major concern for patients, physicians, and those involved in the development of new drugs. A number of studies have shown that the incidence of DILI varies from 1.4 to 19.1/100,000. Overall, women have a 1.5-1.7 times greater risk of developing adverse drug reactions, and the ratio of women to men increases after 49 years, suggesting a clear predisposition to DILI after menopause. In this regard, the study of the causes of the development of DILI depending on the sex differences of patients is relevant today.
Objective: A literature review focusing on epidemiological aspects, pathogenetic mechanisms of formation, and aspects of liver injury in DILI, depending on the gender of the patients.
Search strategy. The search for scientific publications was carried out in the databases of evidence-based medicine (PubMed, Scopus, Cochrane Library, Medline), in electronic scientific resources (e-Library, CyberLeninka, medical sites of neighboring countries), which revealed about 135 literary sources, 79 of them are included in this review. The search depth was 30 years (1992 - 2022). This is due to the importance of foundational fundamental works that reveal the basic issues of epidemiology, pathogenesis and diagnostic foundations for the development of DILI in representatives of various gender groups. This kind of gender-sensitive research has not been done.
Inclusion criteria: the results of modern studies performed taking into account all the requirements of evidence-based medicine; data from basic fundamental studies conducted on various groups; English and Russian-language publications.
Exclusion criteria: "case report"; sources earlier than 1992 that do not meet the requirements of evidence-based medicine; theses.
Results: A review of sources has shown that understanding the epidemiological and pathogenetic mechanisms of the development of DILI can prevent or delay liver damage and the development of related complications, as well as allow screening and identification of risk groups for a subsequent personalized approach to the management of this group.
Conclusions: The epidemiology of DILI is largely underestimated, while severity and clinical course can vary significantly across studies. It is reported that women have a 1.5-1.7 times higher risk of developing adverse drug reactions. Differences in pharmacokinetics, pharmacodynamic gene expression, or activity of drug-metabolizing enzymes may explain the observed differences between men and women, and sex hormones may also play a role.
Gulnara G. Bedelbayeva1, https://orcid.org/0000-0002-4237-0478
Venera S. Rakhmetova2, https://orcid.org/0000-0001-5721-6409
Bayan B. Kamalova1, https://orcid.org/0009-0008-6616-3917
Elena B. Uzhegova1, https://orcid.org/0009-0002-2625-6154
Bazarbay E. Erdash1, https://orcid.org/0009-0002-2762-270Kh
1 Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan,
2 NJSC "Medical University of Astana", Astana, Republic of Kazakhstan.
1. Abajo F.J., Montero D., Madurga M., García Rodríguez L.A. Acute and clinically relevant drug-induced liver injury: a population-based case-control study // Br J Clin Pharmacol. 2004, Jul. 58(1):71-80.
2. Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., Hunt C.M., Wilke R.A., Avigan M., Kaplowitz N., Bjornsson E., Daly A.K. Case definition and phenotype standardization in drug-induced liver injury // Clin Pharmacol Ther. 2011. Jun. 89(6):806-15.
3. Aithal P.G., Day C.P. The natural history of histologically proved drug induced liver disease // Gut. 1999 May. 44(5):731-5.
4. Amacher D.E. Female gender as a susceptibility factor for drug-induced liver injury // Hum Exp Toxicol. 2014 Sep. 33(9):928-39.
5. Anderson G.D. Gender differences in pharmacological response // Int Rev Neurobiol. 2008. 83:1-10.
6. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E. et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period // Gastroenterology. 2005 Aug.129(2):512-21.
7. Bessone F., Hernandez N., Mendizabal M., Sanchez A., Paraná R., Arrese M. et al. When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American Dili Network (Latindilin) // Clin Liver Dis (Hoboken). 2019. Mar 4. 13(2):51-57.
8. Bizzaro D., Crescenzi M., Di Liddo R., Arcidiacono D., Cappon A., Bertalot T. et al. Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury // Clin Sci (Lond). 2018 Jan 25. 132(2):255-272.
9. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., Neuhauser M., Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis // Hepatology. 2010 Jun. 51(6):2040-8.
10. Björnsson E.S., Bergmann O.M., Björnsson H.K., Kvaran R.B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland // Gastroenterology. 2013 Jun. 144(7):1419-25.
11. Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management // Eur J Intern Med. 2022. Mar. 97:26-31.
12. Cardoso H., Vale A.M., Rodrigues S., Gonçalves R., Albuquerque A. et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis // J Hepatol. 2016 Nov. 65(5):1070-1071.
13. Carey J.L., Nader N., Chai P.R., Carreiro S. et al. Drugs and medical devices: adverse events and the impact of women's health // Clin Ther, 2017. 39. pp.10-22.
14. Chalasani N., Bonkovsky H.L., Fontana R., Lee W., Stolz A., Talwalkar J., Reddy K.R., et al. United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN Prospective Study // Gastroenterology. 2015 Jun. 148(7):1340-52.e7.
15. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury // Am J Gastroenterol. 2014. Jul. 109(7):950-66.
16. Chen T.S., Doong M.L., Chang F.Y., Lee S.D., Wang P.S. Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats // Am J Physiol. 1995. Jan, 268(1 Pt 1):G171-6.
17. Church R.J., Kullak-Ublick G.A., Aubrecht J., Bonkovsky H.L., Chalasani N. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort // Hepatology. 2019. Feb. 69(2):760-773.
18. Conti F., Buonfiglioli F., Scuteri A., Crespi C., Bolondi L. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals // J Hepatol. 2016 Oct. 65(4):727-733.
19. Court M.H. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system // Drug Metab Rev. 2010 Feb. 42(1):209-24.
20. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Pirmohamed M., Aithal G.P., Day C.P. et al. DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin // Nat Genet. 2009 Jul. 41(7):816-9.
21. Dash S., Aydin Y., Widmer K.E., Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment // J Hepatocell Carcinoma. 2020 Apr 15. 7:45-76.
22. De Martin E., Michot J.M., Papouin B., Champiat S., Mateus C., Lambotte O. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors // J Hepatol. 2018 Jun. 68(6):1181-1190.
23. De Martin E., Michot J.M., Rosmorduc O., Guettier C., Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors // JHEP Rep. 2020 Aug 11. 2(6):100170.
24. De Valle M.B., Av Klinteberg V., Alem N., Olsson R., Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic // Aliment Pharmacol Ther. 2006. Oct 15, 24(8):1187-95.
25. Devarbhavi H., Dierkhising R., Kremers W.K., Sandeep M.S., Karanth D., Adarsh C.K. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality // Am J Gastroenterol. 2010. Nov. 105(11):2396-404.
26. Dokmak S., Paradis V., Vilgrain V., Sauvanet A., Farges O., Valla D., Bedossa P., Belghiti J. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas // Gastroenterology. 2009 Nov. 137(5):1698-705.
27. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury // J Hepatol. 2019 Jun. 70(6):1222-1261.
28. Faillaci F., Marzi L., Critelli R., Milosa F., Schepis F., Turola E. et al. Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals // Hepatology. 2018 Sep. 68(3):1010-1024.
29. Fletcher C.V., Acosta E.P., Strykowski J.M. Gender differences in human pharmacokinetics and pharmacodynamics // J Adolesc Health. 1994 Dec. 15(8):619-29.
30. Foulds C.E., Treviño L.S., York B., Walker C.L. Endocrine-disrupting chemicals and fatty liver disease // Nat Rev Endocrinol. 2017 Aug. 13(8):445-457.
31. Gerussi A., Natalini A., Antonangeli F., Mancuso C., Agostinetto E., Barisani D., Di Rosa F., Andrade R., Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models // Int J Mol Sci. 2021 Apr 27. 22(9):4557.
32. Hardt A., Stippel D., Odenthal M., Hölscher A.H., Dienes H.P., Drebber U. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report // Case Rep Pathol. 2012. 2012:195607.
33. Hoofnagle J.H., Björnsson E.S. Drug-Induced Liver Injury - Types and Phenotypes // N Engl J Med. 2019. Jul 18. 381(3):264-273.
34. Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A // Biochem Pharmacol. 1992. Jul 22. 44(2):275-83.
35. Idda M.L., Campesi I., Fiorito G., Vecchietti A., Urru S.A.M., Solinas M.G., Franconi F., Floris M. Sex-Biased Expression of Pharmacogenes across Human Tissues // Biomolecules. 2021 Aug 13. 11(8):1206.
36. Kagawa T., Shirai Y., Oda S., Yokoi T. Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats // Toxicol Sci. 2018 Nov 1;166(1):228-239.
37. Katarey D., Verma S. Drug-induced liver injury // Clin Med (Lond). 2016 Dec. 16(Suppl 6): s104-s109.
38. Kim S.H., Saide K., Farrell J., Faulkner L., Tailor A., Pirmohamed M., Park B.K., Naisbitt D.J. et al. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury // Hepatology. 2015. Sep. 62(3):887-99.
39. Kozbial K., Moser S., Schwarzer R., Laferl H. et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment // J Hepatol. 2016 Oct. 65(4):856-858.
40. Kurosaki K., Uesawa Y. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions // Biomolecules. 2021 Jun 25. 11(7):944.
41. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., Fackenthal J.D., Rogan P.K., Ring B., Wrighton S.A., Schuetz E.G. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression // J Pharmacol Exp Ther. 2003. Dec 15. 307(3):906-22.
42. Lemiale V., Meert A.P., Vincent F., Darmon M., Bauer P.R. et al. Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH). Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? // Ann Intensive Care. 2019 Feb 1. 9(1):25.
43. Lemos A.S., Ghabril M., Rockey D.C., Gu J., Barnhart H.X., Fontana R.J., Kleiner D.E., Bonkovsky H.L. Drug-Induced Liver Injury Network (DILIN). Amoxicillin-Clavulanate-Induced Liver Injury // Dig Dis Sci. 2016 Aug. 61(8):2406-2416.
44. Licata A. Adverse drug reactions and organ damage: The liver // Eur J Intern Med. 2016 Mar. 28:9-16.
45. Licata A., Calvaruso V., Cappello M., Craxì A., Almasio P.L. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication // Dig Liver Dis. 2010 Feb. 42(2):143-8.
46. Licata A., Minissale M.G., Calvaruso V., Craxì A. A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort // Eur Rev Med Pharmacol Sci. 2017 Mar. 21(1 Suppl):112-121.
47. Liu W., Zeng X., Liu Y., Liu J., Li C., Chen L., Chen H., Ouyang D. The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury // Front Pharmacol. 2021. Oct 15. 12:723940.
48. Lucena M.I., Molokhia M., Shen Y., Urban T.J., Aithal G.P. et al. Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles // Gastroenterology. 2011 Jul. 141(1):338-47.
49. Mawatari S., Kumagai K., Oda K., Tabu K., Ijuin S., Fujisaki K. et al. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus // PLoS One. 2022 Jan 12. 17(1):e0262267.
50. Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G. et al. Incidence of drug-induced liver injury in medical inpatients // Eur J Clin Pharmacol. 2005. Apr. 61(2):135-43.
51. Miller E.D., Abu-Sbeih H., Styskel B., Nogueras Gonzalez G.M., Blechacz B., Naing A., Chalasani N. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors // Am J Gastroenterol. 2020. Feb, 115(2):251-261.
52. Nakatani T., Roy G., Fujimoto N., Asahara T., Ito A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin // Jpn J Cancer Res. 2001 Mar. 92(3):249-56.
53. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production // Science. 2007 Jul 6. 317(5834):121-4.
54. Nicolson T.J., Mellor H.R., Roberts R.R. Gender differences in drug toxicity // Trends Pharmacol Sci. 2010 Mar. 31(3):108-14.
55. Peeraphatdit T.B., Wang J., Odenwald M.A., Hu S., Hart J., Charlton M.R. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation // Hepatology. 2020 Jul. 72(1):315-329.
56. Roth S.E., Avigan M.I., Bourdet D., Brott D., Church R., Dash A., Keller D., Sherratt P., Watkins P.B., Westcott-Baker L., Lentini S. et al. Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development. // Clin Pharmacol Ther. 2020 Feb. 107(2):333-346.
57. Russo M.W., Steuerwald N., Norton H.J., Anderson W.E., Foureau D., Chalasani N. et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance // Liver Int. 2017 May. 37(5):757-764.
58. Sakiani S., Olsen N.J., Kovacs W.J. Gonadal steroids and humoral immunity // Nat Rev Endocrinol. 2013. Jan, 9(1):56-62.
59. Sapena V., Enea M., Torres F., Celsa C., Rios J., Rizzo G.E.M. et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis // Gut. 2022 Mar. 71(3):593-604.
60. Schomaker S., Warner R., Bock J., Johnson K., Potter D., Van Winkle J., Aubrecht J. Assessment of emerging biomarkers of liver injury in human subjects // Toxicol Sci. 2013 Apr. 132(2):276-83.
61. Schwartz J.B. The influence of sex on pharmacokinetics // Clin Pharmacokinet. 2003. 42(2):107-21.
62. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., Lenoir C., Lemoine A., Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study // Hepatology. 2002 Aug. 36(2):451-5.
63. Shen T., Liu Y., Shang J., Xie Q., Li J., Yan M. et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China // Gastroenterology. 2019 Jun. 156(8):2230-2241.e11.
64. Solbach P., Potthoff A., Raatschen H.J., Soudah B., Lehmann U. et al. Testosterone-receptor positive hepatocellular carcinoma in a 29-year-old bodybuilder with a history of anabolic androgenic steroid abuse: a case report // BMC Gastroenterol. 2015 May 20. 15:60.
65. Stoot J.H., Coelen R.J., De Jong M.C., Dejong C.H. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases // HPB (Oxford). 2010 Oct. 12(8):509-22.
66. Takikawa H., Murata Y., Horiike N., Fukui H., Onji M. Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006 // Hepatol Res. 2009 May. 39(5):427-31.
67. Thulin P., Nordahl G., Gry M., Yimer G., Aklillu E., Makonnen E. et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts // Liver Int. 2014 Mar. 34(3):367-78.
68. Tian Y., Abu-Sbeih H., Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis // Adv Exp Med Biol. 2018. 995:159-164.
69. Van Steenbergen W., Peeters P., De Bondt J., Staessen D., Büscher H., Laporta T., Roskams T., Desmet V. Nimesulide-induced acute hepatitis: evidence from six cases // J Hepatol. 1998. Jul. 29(1):135-41.
70. Vega M., Verma M., Beswick D., Bey S., Hossack J., Merriman N., Shah A., Navarro V. Drug Induced Liver Injury Network (DILIN). The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware // Drug Saf. 2017 Sep. 40(9):783-787.
71. Villani R., Facciorusso A., Bellanti F., Tamborra R., Piscazzi A. et al. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment // PLoS One. 2016 Dec 20. 11(12):e0167934.
72. Villanueva-Paz M., Morán L., López-Alcántara N., Freixo C., Andrade R.J., Lucena M.I., Cubero F.J. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice // Antioxidants (Basel). 2021. Mar 5. 10(3):390.
73. Waller P., Shaw M., Ho D., Shakir S., Ebrahim S. Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database // Br J Clin Pharmacol. 2005, Feb. 59(2):213-9.
74. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L.E., Galas D.J. Circulating microRNAs, potential biomarkers for drug-induced liver injury // Proc Natl Acad Sci USA. 2009 Mar 17. 106(11):4402-7.
75. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes // Mol Pharmacol. 2009 Aug. 76(2):215-28.
76. Wong M.C.S., Huang J.L.W., George J., Huang J., Leung C., Eslam M., Chan H.L.Y., Ng S.C. The changing epidemiology of liver diseases in the Asia-Pacific region // Nat Rev Gastroenterol Hepatol. 2019 Jan. 16(1):57-73.
77. Woodward C., Smith J., Acreman D., Kumar N. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use // Ann Hepatobiliary Pancreat Surg. 2019 May. 23(2):174-177.
78. Yuan L., Kaplowitz N. Mechanisms of drug-induced liver injury // Clin Liver Dis. 2013. Nov. 17(4):507-18, vii.
79. Zucman-Rossi J., Jeannot E., Nhieu J.T., Scoazec J.Y., Guettier C., Rebouissou S. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC // Hepatology. 2006 Mar. 43(3):515-24.
Number of Views: 440
Category of articles:
Reviews
Bibliography link
Bedelbayeva G.G., Rakhmetova V.S., Kamalova B.B., Uzhegova E.B., Erdash B.E. Drug-induced liver injury and gender differences // Nauka i Zdravookhranenie [Science & Healthcare]. 2024, (Vol.26) 1, pp. 179-190. doi 10.34689/SH.2024.26.1.022Related publications:
EVIDENCE-BASED NURSING PRACTICE. LITERATURE REVIEW
DEVELOPMENT OF AN ALGORITHM FOR DISPENSARY OBSERVATION OF PATIENTS WHO UNDERWENT CORONARY ARTERY BYPASS GRAFTING
PSYCHOEMOTIONAL STATUS IN PATIENTS WITH CHRONIC HEART FAILURE. LITERATURE REVIEW.
ENDOSCOPIC TREATMENT OF BLEEDING OF THE UPPER GASTROINTESTINAL TRACT.LITERARY REVIEW.
ACTUAL PROBLEMS OF THE USE MODERN INTRAMEDULLARY TELESCOPIC RODS USED IN THE SURGICAL TREATMENT OF OSTEOGENESIS IMPERFECTA IN CHILDREN. REVIEW.